Christopher is the Managing Director of Bull & Bear Life Sciences and has over 8 years of experience, starting out as a blue-chip consultant before moving into industry to drive business planning, forecasting and strategy in various roles. He now works with a range of biopharmaceutical and medical companies, specialising in portfolio optimisation, business planning and forecast modelling.
Christopher holds a BSc in Biology from Bristol University and a MSc in Molecular Medicine from Imperial College. He is an ACA qualified Chartered Accountant and a passionate investor.
Avi is a strategic and commercial expert with over 20 years of experience in large, medium and small pharmaceutical companies.
Avi has extensive experience launching, commercialising and building growth for product portfolios, optimising brand performance across the full product lifecycle from Phase 1 through to loss of exclusivity, with experience in many major therapy areas, oncology and rare disease.
Portfolio strategy is crucial when managing a range of assets across various stages of development. Our consultants collaborate with cross-functional teams to provide first-class modelling, simulation and commercial insight within client portfolios from early stage and pre-launch through to loss of exclusivity, enabling clients to make key strategic decisions.
We help companies optimise R&D investment and ‘go/no-go’ decisions by assessing early-stage pipeline potential.
We assist companies in maximising product value by assessing potential options for geographical expansion, and optimal operating and commercial structures.
We collaborate with companies to enhance value across the in-market lifecycle, from early launch phase through to LOE. Our vast experience in strategic planning, forecasting and commercial leadership enables us to ask key strategic questions while providing high quality analysis and recommendations.
Combining strong experience and expertise in financial advisory and life sciences, we are able to advise clients across all stages of the deal cycle, including commercial assessments, acquisitions, in-licensing and out-licensing.
Portfolio strategy is crucial when managing a range/class of assets. Our consultants collaborate with cross-functional teams to provide first-class modelling and simulation of client portfolios from early stage/pre-launch through to loss of exclusivity, driving key strategic decisions.
We help companies optimise R&D investment and ‘go/no-go’ decisions by assessing overall early-stage pipeline potential. This includes in-depth qualitative and quantitative evaluation of portfolio assets driven by first-class analysis and commercial expertise.
We assist companies in maximising product value whether at late-stage development or product launch, by assessing various options for geographical expansion, optimal operating and commercial structures, while maintaining focus on maximising profitability and ROI.
We collaborate with companies in enhancing value across the in-market lifecycle, from early launch/growth phase through to LOE. Our vast experience in strategic planning, forecasting and commercial leadership enables us to ask key strategic questions while providing high quality analysis and recommendations.
Combining strong experience and expertise in financial advisory and life sciences, we are able to advise clients across all stages of the deal cycle, including commercial assessments, acquisitions, in-licensing and out-licensing.
Every project is unique and that is why we strive to deliver bespoke and creative solutions for our clients rather than looking to solve ‘off-the-shelf’.
We offer a continuity in service that is all too rare in consultancy with strong client relationships at the focal point of our ethos.
We provide a unique combination of analytical and commercial skills and experience, with our consultants coming from a range of backgrounds.
